The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

Learn how psoriasis, allergies, and eczema are connected and how they're different. Get lifestyle tips on managing both.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

CMO, director of clinical research at Frontier Dermatology in Mill Creek, Washington, discussed studies presented at Maui Derm 2026 that examined high-impact psoriasis sites.

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

More than eight million people in the United States have the autoimmune skin condition known as psoriasis, according to the National Psoriasis Foundation. Psoriasis is a chronic condition. There’s no ...

Risankizumab is effective through 2.5 years of treatment among patients with psoriasis, with most patients achieving rapid and sustained response.

Psoriasis can easily be mistaken for other difficult-to-deal-with skin problems, like a bad infection or rash, eczema, or dermatitis. And because it varies in severity, it can be tricky to figure out ...